Levels of miR‐31 and its target genes in dermal mesenchymal cells of patients with psoriasis

Wang, Qiang; Chang, Wenjuan; Yang, Xiaohong; Cheng, Yueai; Zhao, Xincheng; Zhou, Ling; Li, Juan; Li, Junqin; Zhang, Kaiming

doi:10.1111/ijd.14197

Cited by 19 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is supported in transcriptomics by the involvement of proangiogenetic genes which are already expressed in non-lesional psoriatic skin [174]. Dermal mesenchymal stem cells are discussed as potential contributors in regulating angiogenesis in the skin [175][176][177][178]. In addition, anti-TNFα treatment led to the upregulation of VEGF negative regulating pathways [179].…”

Section: Dcsmentioning

confidence: 93%

Review—Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis

Schwingen

Kaplan

Kurschus

2020

IJMS

View full text Add to dashboard Cite

During the last decades, high-throughput assessment of gene expression in patient tissues using microarray technology or RNA-Seq took center stage in clinical research. Insights into the diversity and frequency of transcripts in healthy and diseased conditions provide valuable information on the cellular status in the respective tissues. Growing with the technique, the bioinformatic analysis toolkit reveals biologically relevant pathways which assist in understanding basic pathophysiological mechanisms. Conventional classification systems of inflammatory skin diseases rely on descriptive assessments by pathologists. In contrast to this, molecular profiling may uncover previously unknown disease classifying features. Thereby, treatments and prognostics of patients may be improved. Furthermore, disease models in basic research in comparison to the human disease can be directly validated. The aim of this article is not only to provide the reader with information on the opportunities of these techniques, but to outline potential pitfalls and technical limitations as well. Major published findings are briefly discussed to provide a broad overview on the current findings in transcriptomics in inflammatory skin diseases.

show abstract

Section: Dcsmentioning

confidence: 93%

Review—Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis

Schwingen

Kaplan

Kurschus

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In PsA patients, serum complement component 3 (C3) levels were reported higher than in control group 22 . Since prolargin has previously been shown to inhibit the alternative pathway C3 convertase 21 , and its expression to be 1.35-fold higher in psoriasis group compared to controls in miR-31 microarray assay 23 , it is likely relevant to PsA as well. Indeed, prolargin was recently suggested as a new protein candidate indicative of response to anti-tumor necrosis factor (TNF)-α in PsA, thus warranting further investigation of this protein in this disease 24 .…”

Section: Introductionmentioning

confidence: 99%

A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis

Sinkevičiūtė

Groen

Sun

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Psoriatic arthritis (PsA) is a chronic musculoskeletal inflammatory disease found in up to 30% of psoriasis patients. Prolargin—an extracellular matrix (ECM) protein present in cartilage and tendon—has been previously shown elevated in serum of patients with psoriasis. ECM protein fragments can reflect tissue turnover and pathological changes; thus, this study aimed to develop, validate and characterize a novel biomarker PROM targeting a matrix metalloproteinase (MMP)-cleaved prolargin neo-epitope, and to evaluate it as a biomarker for PsA. A competitive ELISA was developed with a monoclonal mouse antibody; dilution- and spiking-recovery, inter- and intra-variation, and accuracy were evaluated. Serum levels were evaluated in 55 healthy individuals and 111 patients diagnosed with PsA by the CASPAR criteria. Results indicated that the PROM assay was specific for the neo-epitope. Inter- and intra- assay variations were 11% and 4%, respectively. PROM was elevated (p = 0.0003) in patients with PsA (median: 0.24, IQR: 0.19–0.31) compared to healthy controls (0.18; 0.14–0.23) at baseline. AUROC for separation of healthy controls from PsA patients was 0.674 (95% CI 0.597–0.744, P < 0.001). In conclusion, MMP-cleaved prolargin can be quantified in serum by the PROM assay and has the potential to separate patients with PsA from healthy controls.

show abstract

“…We observed that MSCs from the skin showed an immunophenotype that was similar to that of BM-MSCs because there were no statistically significant differences in the expression levels of the markers that were analyzed, except in the expression of HLA-I, whose relevance will be discussed later. Previous studies have described the presence of MSCs in the dermis derived from healthy donors and patients with psoriasis, although in some cases, a complete characterization has not been performed [23]. For example, a previous study reported the presence of multipotential mesenchymal stem cells in the foreskin but did not determine the expression of CD73, HLA-I, or HLA-II or the chondrogenic differentiation capacity of the cells [24].…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stromal Cells from the Epidermis and Dermis of Psoriasis Patients: Morphology, Immunophenotype, Differentiation Patterns, and Regulation of T Cell Proliferation

Castro-Manrreza

Bonifaz

Castro-Escamilla

et al. 2019

Stem Cells International

View full text Add to dashboard Cite

Psoriasis is a skin disease characterized by hyperproliferation of keratinocytes and chronic inflammation. Mesenchymal stem/stromal cells (MSCs) exhibit an immunoregulatory function that can be altered in the skin of these patients. However, to date, the presence and functional capacity of MSCs in the dermis and epidermis of patients with psoriasis have not been fully established. In the present study, we evaluated the presence of MSCs in the skin of patients by obtaining adherent cells from the dermis and epidermis of lesional and nonlesional areas and characterizing them in a comparative manner with corresponding cells obtained from the dermis (HD-MSCs) and epidermis (HE-MSCs) of healthy donors. We determined whether the adherent cells had immunophenotypic profiles and differentiation potentials that were characteristic of MSCs. In addition, we analyzed their immunosuppression function by evaluating their capacity to decrease T cell proliferation. Our results indicate the presence of MSCs in the dermis and epidermis of healthy donors and patients with psoriasis; adherent cells from all skin sources exhibited MSC characteristics, such as expression of CD73, CD90, and CD105 markers and a lack of hematopoietic and endothelial marker expression. However, the cell populations obtained showed differences in differentiation potential toward adipogenic, osteogenic, and chondrogenic lineages. In addition, we observed a low MSC obtention frequency in nonlesional epidermal samples (NLE-MSCs), which also showed alterations in morphology and proliferation rate. Interestingly, MSCs from both the nonlesional dermis (NLD-MSCs) and lesional dermis (LD-MSCs) showed higher HLA class I antigen (HLA-I) expression than HD-MSCs. Moreover, NLD-MSCs showed a low T cell proliferation suppression capacity. In summary, this study demonstrates the presence of MSCs in the epidermis and dermis of patients with psoriasis and suggests that such cells may favor the inflammatory process and thus psoriatic lesion development through high HLA-I expression and low immunosuppression capacity.

show abstract

Levels of miR‐31 and its target genes in dermal mesenchymal cells of patients with psoriasis

Cited by 19 publications

References 28 publications

Review—Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis

Review—Current Concepts in Inflammatory Skin Diseases Evolved by Transcriptome Analysis: In-Depth Analysis of Atopic Dermatitis and Psoriasis

A novel biomarker of MMP-cleaved prolargin is elevated in patients with psoriatic arthritis

Mesenchymal Stromal Cells from the Epidermis and Dermis of Psoriasis Patients: Morphology, Immunophenotype, Differentiation Patterns, and Regulation of T Cell Proliferation

Contact Info

Product

Resources

About